Dalfampridine
- Generic Name
- Dalfampridine
- Brand Names
- Ampyra, Fampyra, Fampridine Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C5H6N2
- CAS Number
- 504-24-5
- Unique Ingredient Identifier
- BH3B64OKL9
- Background
Dalfampridine is a potassium channel blocker used to help multiple sclerosis patients walk. This is the first drug that was specifically approved to help with mobility in these patients. FDA approved on January 22, 2010.
- Indication
Dalfampridine is a neurofunctional modifier that helps improve walking speed in patients with multiple sclerosis (MS).
- Associated Conditions
- Multiple Sclerosis
- Associated Therapies
- -
A New Medicine to Treat Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)
- Conditions
- Interventions
- First Posted Date
- 2013-11-03
- Last Posted Date
- 2016-01-25
- Lead Sponsor
- Neuro-Ophthalmologic Associates, PC
- Target Recruit Count
- 20
- Registration Number
- NCT01975324
- Locations
- 🇺🇸
Neuro-Ophthalmologic Associates, PC, Philadelphia, Pennsylvania, United States
Dalfampridine and Gait in Spinocerebellar Ataxias
- Conditions
- Interventions
- First Posted Date
- 2013-03-14
- Last Posted Date
- 2015-01-12
- Lead Sponsor
- University of Florida
- Target Recruit Count
- 20
- Registration Number
- NCT01811706
- Locations
- 🇺🇸
University of Florida, Gainesville, Florida, United States
Short and Long Term Treatment With 4-AP in Ambulatory SMA Patients
- First Posted Date
- 2012-07-20
- Last Posted Date
- 2016-05-18
- Lead Sponsor
- Columbia University
- Target Recruit Count
- 11
- Registration Number
- NCT01645787
- Locations
- 🇺🇸
Columbia University Medical Center, New York, New York, United States
Combination Therapy With Dalfampridine and Locomotor Training for Chronic, Motor Incomplete Spinal Cord Injury
- First Posted Date
- 2012-06-18
- Last Posted Date
- 2017-12-02
- Lead Sponsor
- Kessler Foundation
- Target Recruit Count
- 27
- Registration Number
- NCT01621113
- Locations
- 🇺🇸
Kessler Institute for Rehabilitation, West Orange, New Jersey, United States
4-Aminopyridine in Episodic Ataxia Type 2
- First Posted Date
- 2012-03-05
- Last Posted Date
- 2020-11-16
- Lead Sponsor
- University of California, Los Angeles
- Registration Number
- NCT01543750
- Locations
- 🇺🇸
University of California, Los Angeles (UCLA), Los Angeles, California, United States
🇺🇸University of South Florida, Tampa, Florida, United States
🇺🇸University of Rochester School of Medicine, Rochester, New York, United States
Fampridine Pregnancy Exposure Registry
- Conditions
- First Posted Date
- 2012-02-14
- Last Posted Date
- 2016-10-18
- Lead Sponsor
- Biogen
- Target Recruit Count
- 1
- Registration Number
- NCT01532154
- Locations
- 🇫🇷
Hopital Pitie Salpetriere, Paris, France
An Observational Study to Collect Information on Safety and to Document the Drug Utilization of Fampyra (BIIB041) When Used In Routine Medical Practice
- First Posted Date
- 2011-11-28
- Last Posted Date
- 2019-06-05
- Lead Sponsor
- Biogen
- Target Recruit Count
- 4734
- Registration Number
- NCT01480063
- Locations
- 🇪🇸
Site Research, Bilbao, Vizcaya, Spain
🇪🇸Research site, San Cristobal de La laguna, Tenerife, Spain
🇨🇦Reasearch Center, London, Ontario, Canada
Open-Label Study to Assess the Effect of Long-Term Prolonged-Release Fampridine (BIIB041) on Quality of Life as Reported by Participants With Multiple Sclerosis
- First Posted Date
- 2011-11-28
- Last Posted Date
- 2017-03-21
- Lead Sponsor
- Biogen
- Target Recruit Count
- 901
- Registration Number
- NCT01480076
- Locations
- 🇬🇧
Research Site, London, United Kingdom
Dalfampridine for Imbalance in Multiple Sclerosis
- First Posted Date
- 2011-09-30
- Last Posted Date
- 2014-06-16
- Lead Sponsor
- Oregon Health and Science University
- Target Recruit Count
- 24
- Registration Number
- NCT01444300
- Locations
- 🇺🇸
Oregon Health and Science University, Portland, Oregon, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.